GenFleet Receives EMA Approval to Study GFH925 + Erbitux (cetuximab) as 1L Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer
Shots:
- The EMA has approved the P-Ib/II study to evaluate the safety/tolerance, efficacy, and PK characteristics of GFH925 (KRASG12C inhibitor) + Erbitux (cetuximab) for the treatment of patients with KRASG12C-mutant NSCLC. GenFleet will first open trial sites in the EU and then initiate a similar trial in China with its partner Innovent
- The P-I study results of GFH925 monotx. at 600mg, the BID dose showed a better efficacy signal with investigator-assessed ORR (61.9%) & DCR (100%). The results were presented at ASCO and CSCO 2022
- GFH925 received the BTD from the NMPA to treat advanced NSCLC patients with KRASG12C mutation that have received one prior line of systemic therapy
Ref: PRNewswire | Image: GenFleet
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
